In compliance with current regulations, let us know which audience you belong to:
We believe Intense Pulsed Light (IPL) is great, but it isn't effective enough. Following years of research, Espansione Group has developed an innovative photobiomodulation technology, Light Modulation® LLLT for the treatment of the ocular surface (anterior segment) and beyond onto the retina with dry AMD applications (currently under LightWave II clinical trial).
Introducing Light Modulation® Low-level Light Therapy—a radically different technology and approach. By pairing it with Optimal Power Energy® IPL, Espansione Group’s very own, enhanced IPL technology, Espansione Group was able to resolve common IPL limitations, setting a new standard in ocular surface treatment.
“Combined OPE® IPL and LM® LLLT therapies in a single treatment produced significant improvements in tear breakup time and MGD grading scores, with an associated improvement in the patient’s subjective OSDI score.”
STONECIPHER, KARL, ET AL. COMBINED LOW LEVEL LIGHT THERAPY AND INTENSE PULSED LIGHT THERAPY FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION. CLINICAL OPHTHALMOLOGY (AUCKLAND, NZ), 2019, 13: 993.
Common IPL technologies can be only applied to the lower eyelids when treating Dry Eye Disease (DED) caused by Meibomian Glands Dysfunction (MGD). This implies that the Meibomian Glands located in the upper eyelid could not be treated.
Thanks to our combined therapy and our innovative design, the treatment of both upper and lower meibomian glands is now possible. In addition, our solutions allow us to treat other common related ocular surface pathologies, such as chalazion, stye, blepharitis, post-blepharoplasty, demodex and dry eye caused by refractive and cataract surgery.